President Trump Announces New Agreements with Pharmaceutical Manufacturers to Lower Drug Prices

President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to implement "most-favored-nation" (MFN) pricing, aiming to lower prescription drug costs for Americans in line with prices paid by other developed nations. These agreements bring the total number of manufacturers with MFN deals to 26, covering 89% of the branded drug market, and include commitments for over $19.6 billion in U.S. manufacturing investments and contributions to the Strategic Active Pharmaceutical Ingredients Reserve.